Current practice of chronic hepatitis B treatment in Southern Italy. by Stroffolini, T. et al.
European Journal of Internal Medicine 23 (2012) e124–e127
Contents lists available at SciVerse ScienceDirect
European Journal of Internal Medicine
j ourna l homepage: www.e lsev ie r .com/ locate /e j imOriginal article
Current practice of chronic hepatitis B treatment in Southern Italy
T. Stroffolini a, A. Spadaro b, V. Di Marco c, G. Scifo d, M. Russello e, G. Montalto f, G. Bertino g,
L. Surace h, B. Caroleo i, G. Foti j, V. Portelli k, S. Madonia l, M. Sapienza m, L. Cosco n,
P. Frugiuele o, A. Galdieri p, N. Brandolino q, R. Siciliano r, S. Bruno s, P.L. Almasio c,⁎
and The Gr.E.Ca.S. Hospitals' Collaborating Group 1
a Department of Infectious and Tropical Diseases, Policlinico Umberto I, Rome, Italy
b U.O.C. di Medicina Interna a Indirizzo Gastroenterologico A.O.U., Messina, Italy
c Gastroenterologia & Epatologia, Di.Bi.M.I.S., Università di Palermo, Italy
d U.O.C. Malattie Infettive Ospedale Umberto I Siracusa, Italy
e U.O.D. di Epatologia A.R.N.A.S. Garibaldi, Catania, Italy
f U.O. di Medicina Interna ed Epatologia Università di Palermo, Italy
g U.O.S di Malattie del Fegato - A.O.U. Policlinico-Vittorio Emanuele, Catania, Italy
h Ambulatorio di Infettivologia ed Epatologia UO Medicina Specialistica Distretto del Lametino ASP Catanzaro, Italy
i U.O. Malattie Infettive A.O. “Mater Domini”, Catanzaro, Italy
j U.O. Malattie Infettive Ospedale Melacrino Morelli, Reggio Calabria, Italy
k U.O. Malattie Infettive Ospedale S. Antonio Abate, Trapani, Italy
l Med. Interna 2 Ospedali Riuniti Villa Soﬁa Cervello, Palermo, Italy
m U.O.C. Malattie Infettive “S. Felice” Ospedale. “C. Basilotta”, Nicosia, Italy
n U.O. Malattie Infettive A.O. “Pugliese-Ciaccio”, Catanzaro, Italy
o U.O.C. Medicina Interna e Reumatologia Ospedale Annunziata A. O. Cosenza, Italy
p U.O. di Medicina Generale, Servizio di Epatologia, Ospedale Crotone, Italy
q U.O.S. di Epatologia A. O.“Bianchi-Melacrino-Morelli” Reggio Calabria, Italy
r U.O.C. Medicina Interna P.O Acireale - ASP Catania, Italy
s U.O.C. Malattie Infettive Ospedale Cutroni Zodda Barcellona Pozzo di Gotto ASP Messina, Italy⁎ Corresponding author at: Gastroenterology and Live
di Medicina Interna e Specialistica (Di.Bi.M.I.S.), Universit
E-mail address: piero.almasio@unipa.it (P.L. Almasio
1 Authors from the collaborating Group of Gr.E.Ca.S.
Siciliano):Morace C., Bronte F., Di StefanoM., Benigno R., L
L., Staltari O., Kunkar A., Savalli F., Perricone G., Benenati P
S., Leotta S., Panella L.
0953-6205/$ – see front matter © 2012 European Feder
doi:10.1016/j.ejim.2012.03.018a b s t r a c ta r t i c l e i n f oArticle history:
Received 25 January 2012
Received in revised form 15 March 2012
Accepted 31 March 2012
Available online 25 April 2012
Keywords:
HBV
Interferon
Nucleosides analogues
Nucleotides analogues
Background: Treatment choice for chronic HBV infection is a continuously evolving issue, with a wide range of
options. We aimed to evaluate the current practice of HBV therapies in the real world in Southern Italy.
Methods: A prospective study enrolling over a six month period (February–July 2010) all consecutive HBsAg
positive subjects, never previously treated, referred to 16 liver units in two Southern Italy regions (Calabria
and Sicily).
Results: Out of 247 subjects evaluated, 116 (46.9%) had HBV-DNA undetectable or lower than 2000 UI/ml.
There were 108 (43.7%) inactive carriers, 103 (41.7%) chronic hepatitis, and 36 (14.6%) liver cirrhosis. Anti-
viral treatment was planned in 94 (38.0%) patients (26 cases with Interferon or Pegylated Interferon and
68 with nucleos(t)ides analogues). As many as 49.5% of subjects with chronic hepatitis did not receive
antiviral treatment.
Discussion: The majority of chronic HBsAg carrier referring centres for evaluation were not considered
suitable for antiviral treatment. Nucleos(t)ides analogues are the preferred ﬁrst choice for therapy. A long-
lasting period of observation may be needed to make appropriate therapeutic decisions in several cases.© 2012 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.r Unit, Dipartimento Biomedico
y of Palermo, Palermo, Italy.
).
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. Quintieri F., Cesario F., Bagnato
ation of Internal Medicine. Publishe1. Introduction
Growing attention has been addressed to hepatitis B virus (HBV)
during the last few years. Current treatment of chronic hepatitis B in-
fection represents an evolving challenge due to the introduction of
several new and effective antiviral agents. There are currently four
major treatment guidelines for therapy of chronic hepatitis B, pub-
lished by the American Association for the Study of the Liver Diseases
(AASLD), the European Association for the Study of the Liver (EASL),
the Asian Paciﬁc Association for the Study of the Liver (APASL) andd by Elsevier B.V. All rights reserved.
Table 1
Treatment criteria for the four major guidelines for therapy of chronic hepatitis B.
Guidelines HBV-DNA (IU/ml) ALT (U/L)
AASLD
HBeAg +ve ≥20,000 >2×ULN
HBeAg −ve ≥20,000 >2×ULN
EASL
HBeAg +ve ≥2000 >ULN
HBeAg −ve ≥2000 >ULN
APASL
HBeAg +ve ≥20,000 >2×ULN
HBeAg −ve ≥20,000 >2×ULN
AISF, SIMaST, SIMIT
HBeAg +ve >20,000 >ULN
HBeAg −ve >2000 >ULN
ASSLD: American Association for the Study of Liver Diseases.
EASL: European Association for the Study of the Liver.
APASL: Asian-Paciﬁc Association for the Study of the Liver.
AISF : Italian Association for the Study of The Liver.
SIMaST, Italian Society for the Study of Sexually Transmitted Diseases.
SIMIT Italian Society of Infectious and Tropical Diseases.
ULN: upper limit of normal.
Table 2
Baseline characteristics of 247 HBsAg positive subjects.
Characteristic
Age (years) (mean±S.D.) 48.9±13.8 (19–82)
Gender
Male 137 (55.5%)
Female 110 (44.5%)
Years of awareness of HBsAg positivitya
≤1 50 (23.3%)
1–5 51 (23.7%)
>5 114 (53.0%)
HBeAg positive 33 (13.4%)
Anti-HDV positive 15 (6.1%)
Anti-HCV positive 15 (6.1%)
Anti-HIV positive 9 (3.6%)
HBV-DNA (IU/ml)
Undetectable 5 (2.0%)
b2000 111 (44.9%)
2000–20,000 43 (17.4%)
>20,000 88 (35.6%)
ALT (ULN)
b1 21 (49.0%)
1–2 64 (25.9%)
2–5 51 (20.6%)
>5 11 (4.5%)
Diagnostic category
Inactive carrier 108 (43.7%)
Chronic hepatitis 103 (41.7%)
Liver cirrhosis 36 (14.6%)
Treatment received
No drug 153 (62.0%)
rIFN/PEG-IFN 26 (10.5%)
Nucleos(t)ide analogues 68 (27.5%)
a Some data are missing. ULN: upper limit of normal.
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these guidelines is the adoption of a different threshold of HBV-DNA
and ALT levels for treatment (Table 1).
Treatment choice is a continuously evolving issue with a wide
range of options. Seven drugs are now available for the treatment
of chronic hepatitis B in Italy. They include recombinant Alpha
Interferon (rIFN), Pegylated Alpha Interferon (PEG-IFN), nucleoside
analogues, Lamivudine (LAM), Telbivudine (LdT), and Entecavir
(ETV), and nucleotide analogues, Adefovir dipivoxyl (ADV) and
Tenofovir (TDF).
However, information on the current practice of HBV treatment in
the real world is lacking. Recently, we have evaluated the effective-
ness of hepatitis C virus (HCV) treatment in Southern Italy [5]. It
has allowed us a good opportunity to evaluate in the same area
even the current practice of HBV infection treatment.
2. Methods
2.1. Study population
During a six month period (February–July 2010) all consecutive
HBsAg positive subjects, who never had previously received antiviral
therapies, referred to 16 liver units located in two southern Italian
Regions (Calabria and Sicily) were recruited. Patients were eligible
for the study if they were older than 18 years of age, had a positive
HBsAg test by ELISA, regardless of HBV-DNA titre. Those that were
found to have decompensated liver cirrhosis or hepatocellular carci-
noma (HCC) were excluded.
At the time of enrolment, all patients received comprehensive
counselling by a treating clinician, including natural history and prog-
nosis of chronic HBV infection and treatment options. The treating
physician at each centre was a gastroenterologist, hepatologist, or
infectious disease specialist who was experienced in the management
of patients with chronic HBV infection. Patients were evaluated for
HBV therapies by the clinician using standardised criteria based on
the current international treatment guidelines.
There is a common way, among the different centres, to manage
HBV naive patients, as all are referral centres members of the Italian
Association Study Liver Diseases (AISF).
Demographic information and results of laboratory testing were
recorded on standardised data collection sheet. Diagnostic criteria
for inactive carrier, chronic hepatitis and liver cirrhosis were used
according to the American guideline [6]. An inactive carrier was de-
ﬁned as a person with persistent HBV infection of the liver withoutsigniﬁcant necroinﬂammation at liver biopsy; chronic hepatitis and
liver cirrhosis as chronic necroinﬂammatory hepatic disease caused
by persistent infection with HBV.
2.2. Laboratory assay
HBV markers, anti-hepatitis C virus (HCV), anti-hepatitis D virus
(HDV), and anti-human immunodeﬁciency virus (HIV) were deter-
mined by ELISA tests. Serum HBV-DNA levels were determined by a
commercial Real Time PCR assay (Abbott, Realtime, USA) with a sen-
sitivity threshold of 10 IU/ml. Laboratory assays were performed in
the various hospitals participating in the investigation.
2.3. Statistical analysis
Continuous variables were expressed as mean and standard devi-
ation (SD), and Student's t test was used. Categorical variables were
reported as absolute and percentage values, and compared by using
chi-squared test. A p valueb0.05 was considered to be signiﬁcant.
All reported p values were two sided.
3. Results
During the study period 247 HBsAg positive subjects were en-
rolled. Their mean age was 48.9 years, with a male preponderance
(55.5%). The majority of subjects (53.0%) reported more than
5 years of awareness of HBsAg positivity. The proportion of HBeAg
positive patients was 13.4%. Co-infection with HDV, or HCV or HIV
was reported in 6.1%, 6.1%, and 3.6% respectively. The majority of
cases (46.9%) had HBV-DNA undetectable or lower than 2000 UI/ml.
Half of cases (49.0%) had normal transaminases values and one-ﬁfth
had >2 normal value. As many as 43.7% of subjects were labelled as
inactive carriers and 14.6% had liver cirrhosis. Antiviral treatment
was planned in 94 (38.0%) subjects. rIFN or PEG-IFN and nucleoside
or nucleotide analogues were given in 10.5% and 27.5% of cases,
Table 3
Comparison of 247 chronic HBsAg according to decision for treatment.
No treatment (n=153) Treatment (n=94) p
Age (years)
(mean±S.D.)
45.9±13.3 53.8±13.4 b0.001
Age (years)
≤30 20 (13.1%) 4 (4.3%) 0.002
31–40 38 (24.8%) 13 (13.8%)
41–50 35 (22.9%) 19 (20.2%)
>50 60 (39.2%) 58 (61.7%)
Gender
Male 80 (52.3%) 57 (60.6%) 0.2
Female 73 (47.7%) 37 (39.4%)
Years of awareness of
HBsAg positivitya
≤1 34 (26.0%) 16 (19.0%) 0.001
1–5 40 (30.5%) 11 (13.1%)
>5 57 (43.5%) 57 (67.9%)
HBeAg positive 20 (13.1%) 13 (13.8%) 0.8
Anti-HDV positive 12 (7.8%) 3 (3.2%) 0.1
Anti-HCV positive 9 (5.9%) 6 (6.4%) 0.9
Anti-HIV positive 8 (5.2%) 1 (1.1%) 0.09
HBV-DNA (UI/ml)a
Undetectable 4 (2.6%) 1 (1.1%) b0.001
b2000 96 (62.7%) 15 (16.0%)
2000–20,000 30 (19.6%) 13 (13.8%)
>20,000 23 (15.0%) 65 (69.1%)
ALT (ULN)
b1 110 (71.9%) 11 (11.7%) b0.001
1–2 27 (17.6%) 37 (39.4%)
2–5 15 (9.8%) 36 (38.3%)
>5 1 (0.7%) 10 (10.6%)
Diagnostic category
Inactive carrier 99 (64.7%) 9 (9.6%) b0.001
Chronic hepatitis 51 (33.3%) 52 (55.3%)
Liver cirrhosis 3 (2.0%) 33 (35.1%)
a Some data are missing. ULN: upper limit of normal.
Table 4
Comparison of chronic HBsAg carriers according to drug received.
rIFN/PEG-IFN
(n=26)
Nucleos(t)ide analogue
(n=68)
p
Age (years) (mean±S.D.) 44.3±11.2 57.4±12.1 b0.001
Age (years)
≤30 2 (7.7%) 2 (2.9%) b0.001
31–40 11 (42.3%) 2 (2.9%)
41–50 6 (23.1%) 13 (19.1%)
>50 7 (26.9%) 51 (75.1%)
Gender
Male 17 (65.4%) 40 (58.8%) 0.56
Female 9 (34.6%) 28 (41.2%)
Years of awareness of HBsAg
positivitya
≤1 4 (17.4%) 12 (19.7%) 0.3
1–5 5 (21.7%) 6 (9.8%)
>5 14 (60.9%) 43 (70.5%)
HBeAg positive 6 (23.1%) 7 (10.3%) 0.1
Anti-HDV positive 1 (3.8%) 2 (2.9%) 0.8
Anti-HCV positive 2 (7.7%) 4 (5.9%) 0.7
Anti-HIV positive 0 1 (1.5%) 0.5
HBV-DNA (UI/ml)a
Undetectable 0 1 (1.5%) 0.7
b2000 3 (11.6%) 12 (17.6%)
2000–20,000 5 (19.2%) 8 (11.8%)
>20,000 18 (69.2%) 47 (69.1%)
ALT (ULN)
b1 5 (19.2%) 6 (8.8%) 0.5
1–2 8 (30.8%) 29 (42.6%)
2–5 10 (38.5%) 26 (38.2%)
>5 3 (11.5%) 7 (10.3%)
Diagnostic category
Inactive carrier 5 (19.2%) 4 (5.8%) b0.001
Chronic hepatitis 20 (76,9%) 32 (47.1%)
Liver cirrhosis 1 (3.9%) 32 (47.1%)
a Some data are missing. ULN: upper limit of normal.
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tients, that could inﬂuence the decisions of a physician was lacking.
Compared to untreated subjects, those who received therapy
were more likely older (mean age 53.8 years vs. 45.9 years,
pb0.01), with longer duration of awareness of HBsAg positivity
(67.9% vs. 43.5%, pb0.01), with altered transaminase values and
with highest proportion of HBV-DNA values at >20,000 UI/ml
(69.1% vs. 15.0%, pb0.01). Note that 51 (49.5%) out of the 103
subjects labelled as having chronic hepatitis did not receive
treatment. In contrast, 9 out of the 108 inactive carriers received
treatment (Table 3). Thirty-two (62.7%) out of the 51 untreated
chronic hepatitis cases had an HBV-DNA titre higher than
2000 UI/ml (data not shown).
Subjects treated with rIFN or PEG-IGN had a more likely mean
younger age (44.3 years vs. 57.9 years, pb0.01) and they were more
likely with chronic hepatitis (76.9% vs. 45.1%, pb0.01) as compared
to those treated with nucleos(t)ide analogues (Table 4).
4. Discussion
Treatment of chronic hepatitis B has greatly changed over the last
few years. Despite the availability of several effective drugs, areas of
uncertainty exist and often therapeutical choices are made on the
basis of evidence that is not fully mature. Moreover, information on
current practice of HBV treatment in the real world is lacking. The
present prospective survey, including patients never previously trea-
ted from several units (thus avoiding the single centre effect) may
provide representative and valuable ﬁndings on this topic.
The large number of centres participating in this study may raise
some concern for the homogeneity with which HBV patients have
been evaluated and treated by the different involved centres. However,
it should be taken into account that all were referral centre membersof the Italian Association Study Liver (AISF), which adopts the samepro-
tocol in the management of HBV patients.
Nearly half of HBsAg carriers referring centres for evaluation have
undetectable HBV-DNA or viral load below the threshold (2000 IU/
ml) considered suitable for treatment. This ﬁgure likely underesti-
mates the true proportion of inactive carriers in the general popula-
tion, because subjects were selected and referred to participating
centres by their general practitioners in order to potentially be trea-
ted. The majority (61.9%) of HBsAg carriers were not considered suit-
able for treatment. Among those treated nucleos(t)ide analogues are
the preferred ﬁrst choice as two-thirds of them receive these drugs.
As expected, subjects treated with rIFN/PEG-IFN are more likely to be
younger and without liver cirrhosis. Co-infection with other viruses
(i.e. HDV, or HCV, or HIV) does not affect the choice.
Some pitfalls in treatment practice emerge. Treatment was pro-
vided to 9 (8.3%) out of the 108 inactive carriers. In contrast, and
more importantly, as many as 51 (49.5%) out of the 103 chronic
hepatitis cases did not receive any treatment despite EASL guide-
lines recommend to treat most of these cases [2]. The latter point
represents a major pitfall. In fact, under treatment of chronic hepa-
titis cases limits the effectiveness of efﬁcacious drugs currently
available for treatment of chronic hepatitis. However, it should be
considered that a limited period of observation cannot be exhaus-
tive to take appropriate decision regarding timing and type of treat-
ment as changes or ﬂuctuation of viral load over time may occur [7].
It may explain why in some chronic hepatitis cases therapy was not
provided during the study period.
Even if we are aware that the short period considered (6 months)
may represent a source of bias that could affect the ﬁndings, this real
world survey may provide the possible, even if not the best, picture
of current treatment practice for HBV infection in Southern Italy.
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view therapeutic choices in actual clinical practice.
The majority of HBsAg carriers don't receive antiviral treatment.
Nucleos(t)ide analogues are the preferred ﬁrst choice for treatment.
A long-lasting period of observation may be needed to make appro-
priate therapeutic decisions in several cases.Learning Points
• Treatment choice of chronic HBV infection is a continuously evolving
issue due to the introduction of several new and effective antiviral
agents
• Information on the current practice of HBV treatment in the real
world is lacking.
• The majority of HBsAg carriers don't receive antiviral treatment.
• Nucleos(t)ide analogues are the preferred ﬁrst choice for treatment.Conﬂict of interest
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